Please ensure Javascript is enabled for purposes of website accessibility

Why Acadia Pharmaceuticals Stock Is Crushing It Today

By Keith Speights – Aug 1, 2019 at 12:06PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Great Q2 results powered by strong momentum for antipsychotic drug Nuplazid have investors fired up.

What happened

Shares of Acadia Pharmaceuticals (ACAD 3.55%) are soaring today, up 17.8% as of 11:27 a.m. EDT, after the drugmaker announced strong second-quarter financial results

So what

The main reason investors are so pumped up about Acadia is due to just how impressive the company's Q2 results were. Acadia reported that its revenue in the second quarter increased 46% year over year to $83.2 million, fueled by continued momentum for antipsychotic drug Nuplazid. This easily topped the consensus Wall Street estimate of a little over $72 million in revenue.

Man with hands held up to the side of his head and a stock chart in the foreground trending upward

Image source: Getty Images.

While Acadia announced a net loss of $54.9 million, or $0.38 per share, its bottom line in Q2 was much better than the net loss of $63 million, or $0.51 per share, in the prior-year period. It also beat analysts' average estimate of a net loss of $0.45 per share.

One quarter of exceeding Wall Street's expectations doesn't change the investing thesis for Acadia, of course. However, the strength for Nuplazid is definitely impressive. And it shows that the company's commercial strategy is working quite well.

Michael Yang, Acadia's chief commercial officer, said in the Q2 conference call that the company's sales team is doing a great job in reaching new prescribers and long-term care pharmacies. He also thought that the transition to the 34 mg tablet and a successful direct-to-consumer campaign were key in Nuplazid's successful quarter.

Now what

Aside from watching how well Acadia continues to execute on its commercialization activities for Nuplazid, the primary things to look forward to for the company are several key pipeline developments. Acadia should begin a late-stage study of trofinetide in treating Rett syndrome in the fourth quarter of 2019. It expects to report results from a study of Nuplazid in treating "negative symptoms" of schizophrenia in December. The company also anticipates announcing interim results from a study of Nuplazid in dementia-related psychosis later this year, with top-line results on the way in the second half of 2020.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Acadia Pharmaceuticals Stock Quote
Acadia Pharmaceuticals
ACAD
$18.69 (3.55%) $0.64

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
339%
 
S&P 500 Returns
109%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.